Related Experiment Videos
Implications of the LIFE trial
Sunil Nadar1, Hoong Sern Lim, Gregory Y H Lip
1University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK.
Expert Opinion on Investigational Drugs
|May 2, 2003
Summary
The LIFE study found that losartan significantly reduced cardiovascular events and left ventricular hypertrophy in hypertensive patients compared to atenolol. This suggests angiotensin receptor blockers may be superior to beta-blockers for hypertension management.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Essential hypertension is a major risk factor for cardiovascular disease.
- Left ventricular hypertrophy (LVH) is a common complication of hypertension, associated with increased cardiovascular risk.
- Current hypertension guidelines recommend various drug classes, but optimal first-line therapy remains debated.
Purpose of the Study:
- To compare the efficacy of losartan (an angiotensin receptor blocker) versus atenolol (a beta-blocker) in reducing cardiovascular morbidity and mortality in patients with essential hypertension and LVH.
- To assess the effects of both treatments on electrocardiographically-defined LVH regression.
- To evaluate the incidence of newly diagnosed diabetes in both treatment groups.
Main Methods:
- The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was a randomized, double-blind, controlled trial.
- Involved patients with essential hypertension and ECG evidence of LVH.
- Primary endpoint: composite of cardiovascular death, myocardial infarction, and stroke.
Main Results:
- Losartan significantly reduced the primary composite endpoint compared to atenolol.
- Losartan demonstrated a greater reduction in LVH compared to atenolol, despite similar blood pressure lowering.
- The atenolol group had a higher incidence of newly diagnosed diabetes.
Conclusions:
- Losartan, an angiotensin receptor blocker, is a highly effective treatment for hypertension, particularly in patients with LVH.
- Losartan offers significant cardiovascular benefits and LVH regression, potentially surpassing beta-blockers like atenolol.
- The findings challenge the role of beta-blockers as first-line monotherapy for hypertension and support the use of ARBs.